/
Oncology
Myeloma
279
Pipeline Programs↗
610
Active Trials↗
186
Companies Involved↗
Myeloma is a highly competitive landscape with 279 programs across 186 companies. The most active players are GSK, Chongqing Precision Biotech Co., Ltd. 57 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical48
Phase 176
Phase 298
Phase 357
Approved
No programs
Analysis
Modality Breakdown
64%
Small molecule
146 of 227 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 227 classified programs, each share of the total. Modality classified for 92% of 279 pipeline programs.
Analysis
Trial Status
2,065
clinical trials
Completed887 · 43%
Recruiting297 · 14%
Terminated283 · 14%
Active, not recruiting212 · 10%
Unknown status173 · 8%
Not yet recruiting98 · 5%
Other115 · 6%
Clinical Trials
Trial Activity
2065 trials
Page 1 of 138
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)